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Abstract Hereditary paroxysmal dyskinesias (PxD) are a het-
erogeneous group of movement disorders classified by frequen-
cy, duration, and triggers of the episodes. A young-adult onset
canine PxD has segregated as an autosomal recessive trait in
Soft-Coated Wheaten Terriers. The medical records and videos
of episodes from 25 affected dogs were reviewed. The episodes
of hyperkinesia and dystonia lasted from several minutes to
several hours and could occur as often as >10/day. They were
not associatedwith strenuous exercise or fasting but were some-
times triggered by excitement. The canine PxD phenotypemost
closely resembled paroxysmal non-kinesigenic dyskinesia
(PNKD) of humans. Whole genome sequences were generated
with DNA from 2 affected dogs and analyzed in comparison to
100 control canid whole genome sequences. The two whole
genome sequences from dogs with PxD had a rare homozygous
PIGN:c.398C > T transition, which predicted the substitution of
an isoleucine for a highly conserved threonine in the encoded
enzyme. All 25 PxD-affected dogs were PIGN:c.398T allele
homozygotes, whereas there were no c.398T homozygotes
among 1185 genotyped dogs without known histories of PxD.
PIGN encodes an enzyme involved in the biosynthesis of
glycosylphosphatidylinositol (GPI), which anchors a variety
of proteins including CD59 to the cell surface. Flow cytometry
of PIGN-knockout HEK239 cells expressing recombinant hu-
man PIGN with the c.398T variant showed reduced CD59 ex-
pression. Mutations in human PIGN have been associated with
multiple congenital anomalies-hypotonia-seizures syndrome-1
(MCAHS1). Movement disorders can be a part of MCAHS1,
but this is the first PxD associated with altered GPI anchor
function.
Keywords Glycosylphosphatidylinositol . Multiple
congenital anomalies-hypotonia-seizures syndrome-1
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Introduction
The human paroxysmal dyskinesias (PxD) are a heteroge-
neous group of diseases characterized by episodes of abnor-
mal involuntary movements [1]. The episodes may last
<1 min or continue for many hours. Episode frequency may
vary from <1/year to >100/day. The abnormal movements can
be dystonia, chorea, athetosis, or ballism, either singly or in
various combinations [2–4]. Many PxD episodes are initiated
by a recognized trigger, and the type of trigger has served as a
means of subclassifying PxD [1, 2, 5]. In paroxysmal exer-
tional dyskinesia (PED), the episodes are triggered by
sustained exercise. Sudden movements trigger the episodes
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in paroxysmal kinesigenic dyskinesia (PKD). In paroxysmal
non-kinesigenic dyskinesia (PNKD), stress, fatigue, and hun-
ger can trigger episodes in some patients, but the most consis-
tent triggers are alcohol or caffeine consumption. Other fac-
tors considered in classification are age of onset, frequency
and duration of the episodes, and response to therapy [1, 2,
5–7].
PxD may be secondary to a specific etiology such as en-
cephalitis or stroke [8] or idiopathic. The latter can be sporadic
or familial, usually with an autosomal dominant inheritance
[5]. Mutations in three genes, SLC2A1, PRRT2, and PNKD
(also referred to asMR-1), are well-recognized causes of PxD
[5, 9–13]. SLC2A1 encodes glucose transport protein 1
(GLUT1), which facilitates glucose transfer across the
blood-brain barrier. Most patients with heterozygous
SLC2A1 mutations exhibit GLUT1-deficiency syndrome
characterized by low CSF-to-blood glucose ratios together
with epilepsy, developmental delay, microcephaly, ataxia,
and PxD [14]. A minority of patients with heterozygous
SLC2A1 mutations develop isolated PED [11, 15–17].
PRRT2 encodes proline-rich transmembrane protein 2, which
interacts with SNAP25 and thereby influences the release of
glutamate or other neurotransmitters [18]. Heterozygous
PRRT2 mutations have been found in patients with several
paroxysmal neurologic disorders including PKD [19]. Many
PNKD patients carry heterozygous mutations in PNKD [5, 6,
13]. This gene encodes a protein that may suppress synaptic
vesicle release by interacting with RIM1 and RIM2 [20].
Although SLC2A1, PNKD, and PRRT2 harbor the majority
of the causal mutations for the genetically defined cases of
PxD [5], a few patients have been reported to carry potentially
causal mutations in other genes such as KCNMA1 [21] and
PDHA1 [22]. Efforts to identify the mutations responsible for
PxD in other families have not yet been successful [6].
Dogs can also develop PxD [23]. Published reports have
provided clinical descriptions of primary canine PxD (cPxD)
or cPxD-like diseases in several breeds including the Bichon
Frise [24], Border Terrier [25], Cavalier King Charles Spaniel
[26], Chinook [27], Doberman Pinscher [28], English Bulldog
[29], Scottish Terrier [30], and Soft-Coated Wheaten Terrier
(SCWT) [31]. Unlike the human primary PxD that are almost
always dominant traits, the cPxD usually have a recessive
mode of inheritance. The cPxD that occurs in the Cavalier
King Charles Spaniel is typically precipitated by exercise
[26]. It is caused by a homozygous 16-kb microdeletion that
includes the first three exons of BCAN [32, 33], which en-
codes the extracellular-matrix protein brevican. The molecular
genetic causes of the other cPxD have not yet been reported.
We now present evidence that SCWTwith cPxD have a defi-
ciency in the biosynthesis of glycosylphosphatidyinositol
(GPI) anchors due to a homozygous missense mutation in




Medical records and available videos of dyskinesia episodes
were reviewed for 22 SCWT and 3 BWhoodles^ (SCWT ×
Poodle crosses) with cPxD. The median age of onset of signs
was 2.25 years. Males and females were affected equally. All
dogs had normal neurologic exams between the episodes.
Episode duration ranged from several minutes up to >4 h,
and the frequency of episodes ranged from 1 every few days
to >10/day. In six cases, stress, excitement, or loud noises
were thought to precipitate some attacks, but a clear trigger
was not apparent in most instances. No dogs had a history of
ingestion of alcohol or caffeine. Typical episodes consisted of
rapid flexion and extension of the hind limbs with varying
degrees of truncal dystonia (Supplementary Video). Most fre-
quently, the flexion alternated irregularly between limbs, but
sometimes both hind limbs were off the ground simultaneous-
ly (Fig. 1). In severe episodes, the front limbs were also af-
fected. No consistent improvement in episodes was reported
with anti-epileptic drugs or benzodiazepines. The signs typi-
cally worsened with age, and six dogs were euthanized within
2 years after onset of signs due to the increasing severity of the
episodes. MRIs were obtained from five affected dogs, and
postmortem exams were performed on four dogs, but no ab-
normalities were identified in any of the examined brains.
Molecular genetics
DNAwas collected from 25 cPxD-affected dogs. In addition,
we used archived DNA samples from 665 cPxD-free SCWT,
388 Poodles, and 132 randomly selected dogs from other
breeds to validate the identified candidate causal variant.
Whole genome sequences were generated with DNA from
two different cPxD-affected SCWT. PCR-based DNA
Fig. 1 A 4-year-old, SCWT during a dyskinesia episode showing
hyperflexion of the hind limbs that elevated both limbs off the ground
simultaneously
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libraries were used for the first whole genome sequence as
previously described [34]. PCR-free DNA libraries and slight-
ly modified procedures [35] were used for the second. Both
data sets were deposited in the Sequence Read Archives (ac-
cession numbers SRX863100 and SRX863101). Previously
described procedures were used for trimming adaptor se-
quences from the sequence reads, eliminating duplicate reads,
error correction, and alignment to the CanFam3.1 canine ref-
erence genome sequence [34, 36]. Sequence variant informa-
tion was uploaded to a custom PostgreSQL database, which
also contained sequence variant information from the aligned
whole genome sequences of normal canids or dogs with dis-
eases other than cPxD. These other sequences served as con-
trols for the current analysis. The University ofMissouri DNA
Core Facility generated 43 of the control dog genome se-
quences; the rest were provided by individuals at other insti-
tutions as indicated in the BAcknowledgements.^
PCR primers 5′-GCTATACTAATATTTCACCGTTC-3′ and
5′-AAAATATAGTAAGTAATACACAA-3′ were used to amplify
a segment of genomic DNA containing candidate sequence
variant PIGN:c.398C > T, identified from the whole genome
sequences, so that the sequence variant could be verified by
direct automated Sanger sequencing. An allelic discrimination
assay [37] was used to genotype DNA samples from individ-
ual dogs at this sequence variant. PCR primers for this assay
were 5′-TGTGGGATTTGATTCTCTTATTAATG-3′ and 5′-
TCAATGACTCTTACCTTTGGCAAACATA-3′. The compet-
ing probe sequences were 5′-VIC-CCAGCTCCATGTGTA
CC-MBG-3′ (reference C allele) and 5′-FAM-CCAGCTCC
ATATGTACC-MBG-3′ (variant T allele).
PIGN-knockout HEK293 cells were generated and
transfected as previously described [38] with human wild-
type or mutant (T133I, T133S, or T133V) PIGN complemen-
tary DNA (DNA) cloned into pME, a strong SRα promoter-
driven expression vector, or pTK, a medium TK promoter-
driven expression vector. These PIGN constructs had an HA
epitope tag at the N-terminus. Transfection efficiencies were
determined by the luciferase activity of cell lysates. After
3 days of incubation, restoration of the cell-surface expression
of CD59 was evaluated by flow cytometry [38]. Levels of
expressed wild-type and mutant HA-tagged PIGN in pME
vector-transfected cells were determined by western blotting
using an anti-HA antibody.
Results
Molecular genetics
Partial pedigree information was available for some of the affect-
ed dogs. Because no records indicated that the sires or dams of
any of the affected dogs also exhibited cPxD, we assumed an
autosomal recessive inheritance in our data analysis.
The first generated whole genome sequence from a
cPxD-affected dog had a 21-fold average coverage of the
reference genome and contained 6.9 million potential se-
quence variants (homozygous or heterozygous differences
from the reference canine genome sequence). When this
sequence variant information was first added to a custom
PostgreSQL database, it also contained sequence variant
information from eight control canine WGSs. The SCWT
sequence variants were filtered to identify only those that
fit three criteria: (1) they were predicted to alter the amino
acid sequence of the gene product (including those that
alter exon-splicing signals), (2) they were homozygous in
the cPxD-affected dog’s whole genome sequence, and (3)
they were absent from the control whole genome se-
quences. In the initial analysis, 418 sequence variants met
these criteria. However, no plausible candidate sequence
variants were identified from a review of the published
biological functions and disease associations for the 302
genes that harbored these sequence variants.
As additional control whole genome sequences were added
to the database, the number of homozygous coding variants
unique to the affected SCWT decreased. Nonetheless, we were
still unable to recognize a potential cPxD-causing sequence
variant. Thus, we generated a whole genome sequence from
another cPxD-affected dog. This sequence had 18-fold average
reference genome coverage and contained 5.5 million potential
sequence variants. By the time that the variants from the second
cPxD-affected SCWT were included in our database, it
contained variant data for 100 canid sequences that could be
considered to be controls for the SCWT PxD. At this time, the
whole genome sequence for the first case SCWTcontained 230
variants in 162 different genes that met our criteria for candidate
causality (Supplementary Table 1a). The whole genome se-
quence for the second SCWT PxD case had 65 candidate var-
iants in 54 different genes (Supplementary Table 1b). The
higher number of variants from the first case is attributable to
the many false positives among the filtered variants from the
early PCR-amplified libraries. The only sequence variant com-
mon to both animals was PIGN:c.398C > T, which predicted a
p. T133I substitution in PIGN, the gene product. Direct auto-
mated Sanger sequencing of PCR amplicons produced with
primers spanning the PIGN:c.398C > T variant confirmed that
both of the SCWT with cPxD were PIGN:c.398T
homozygotes.
All 25 of our DNA samples from cPxD-affected dogs
tested homozygous for the variant PIGN:c.398T allele.
Twenty two of these affected homozygotes were SCWT,
and the other three were Whoodles. Whoodles are marketed
as the product of F1 crosses between purebred SCWT and
purebred Poodles. If this was indeed the origin of the three
c.398T homozygous Whoodles, it would require that the
PIGN:c.398T allele had been segregating in both breeds.
Thus, we genotyped individual representatives from each
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breed at PIGN:c.398C > T. Fifteen of the 682 control SCWT
were heterozygotes; the remaining 667 were homozygous
for reference allele c.398C. All 388 of the genotyped
Poodles were PIGN:c.398C homozygotes, as were all 132
randomly selected representatives of 92 other breeds.
Although the PIGN:c.398T allele was not present in the
Poodles that we genotyped, it could still be carried by other
Poodles. Nonetheless, an alternative and more likely expla-
nation for the origin of the three homozygous Whoodles is
that they resulted from a Whoodle to SCWT backcross or
from two Whoodle parents.
Flow cytometry
The biological activities of mutant PIGN isoforms were
assessed by transiently transfecting corresponding cDNAs
into PIGN-knockout HEK293 cells and measuring the res-
toration of GPI-anchored CD59 surface expression [38,
39]. Flow cytometry of cells which were transfected with
a medium promoter-driven expression vector revealed
comparable restoration of CD59 cell-surface expression
by PIGN-knockout HEK293 cells 3 days after transient
transfection with wild-type human PIGN cDNA or with
recombinant human cDNAs designed to encode PIGN:p.
T133S or PIGN:p. T133V isoforms. However, transient
transfection with recombinant human cDNAs designed
to encode PIGN:p. T133I restored only 60–70% of the
cell-surface CD59 that was produced by the wild-type
cDNA (Fig. 2a). The same T331I PIGN cDNA, when
expressed with a strong promoter-driven vector pME,
nearly fully restored CD59 (Fig. 2a). Western blotting
revealed comparably expressed protein levels of T331I
and wild-type PIGN (Fig. 2b). It is therefore concluded
that the T331I mutation causes a reduction in specific
activity rather than stability of PIGN.
Discussion
We studied a cPxD originally described in SCWT in 2004
[31], which shared features of human PxD. All the affect-
ed dogs were normal on examination between episodes.
The movements appeared to be involuntary and could
not be disrupted. The dogs remained conscious during
the episodes, and except for severe episodes, the dogs
continued to walk, suggesting that the movements were
semi-purposeful. Some of the movements in this cPxD
were the sustained, abnormal postures of a dystonia [40].
The more rapid movements in cPxD are hyperkinetic
movements, but they are difficult to place into one of the
human categories of chorea, ballism, or athetosis [41]. The
various forms of human PxD can be subclassified as a
PED, PKD, or PNKD [1–4, 6, 7]. The owners of dogs
with cPxD never mentioned exercise or fasting as triggers
of dyskinesia episodes as occurs with PED in humans
[42]. Determining whether a sudden movement triggered
the episodes as in PKD in humans [7] was difficult since
the owners typically were not closely observing their dogs
at the onset of the episodes. Compared to the durations
and frequencies of episodes of dyskinesia in human PKD
patients [7], the episodes in dogs with PIGN-associated
cPxD lasted longer (minutes to hours) and occurred less
frequently (several/day to every few weeks), more like
PNKD in humans [6]. Stress and excitement, which trig-
ger episodes in most PNKD associated with PNKD in
humans [6], were reported to trigger the episodes in some
dogs, although in most cases, no trigger could be identi-
fied. While alcohol or caffeine ingestion are the most con-
sistent triggers of human PNKD associated with PNKD
mutations [6], dogs rarely ingest alcohol and methylxan-
thines are toxic to dogs [43], so whether they would trig-
ger episodes in dogs is unknown. PKD patients either
require no treatment or respond to anti-epileptic drugs,
and PNKD patients often respond to benzodiazepines [2,
5–7], while SCWT with cPxD showed a poor response to
these drugs. The median age of onset in dogs was
2.25 years, a young but fully mature adult dog, which
would be older than the equivalent average age of onset
in humans of PNKD associated with PNKD or PKD and
more comparable to Batypical^ PNKD not associated with
PNKD mutations [6, 7]. Thus, even though there are dif-
ferences, the dyskinesia episodes in PIGN-associated
cPxD most closely resemble those of human PNKD
patients.
To identify the molecular genetic cause of cPxD, we
generated whole genome sequences for two affected
dogs. The T allele of a PIGN:c.398C > T transition was
the only rare, homozygous, predicted amino acid altering
sequence variant that was found in both of these animals.
All 25 of our c.398T allele homozygous DNA samples
were from cPxD-affected dogs, whereas none of the 1053
control SCWT and Poodles and none of the 132 geno-
typed dogs from other breeds were c.398T homozygotes.
This established a strong association between the clinical
disease and T allele homozygosity. None of the 15
PIGN:c.398C/T heterozygous SCWT were known to have
exhibited episodes of dyskinesia, which supports the in-
heritance of SCWT cPxD as an autosomal recessive trait.
PIGN is 1 of more than 26 genes that encode the polypep-
tides which contribute to the biosynthesis, protein attachment,
and remodeling of GPI anchors. GPI anchors tether a diverse
group of cell-surface proteins to the plasma membrane
(Fig. 3a). Amide bonds covalently attach the cell-surface pro-
tein to an ethanolamine phosphate at the outer end of the GPI
anchor, while at the inner end, aliphatic chains intercalate into
the plasma membranes and bind to hydrophobic lipid-raft
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components. A complex core glycolipid provides a covalent
bridge between the two ends of the GPI anchor [39, 44].
During GPI assembly in the endoplasmic reticulum, ethanol-
amine phosphate side chains are added to mannosyl moieties
in the core glycolipid. GPI ethanolamine phosphate
transferase-1 (PIGN), the enzyme encoded by PIGN, facili-
tates the transfer of an ethanolamine phosphate from phospha-
tidylethanolamine to the innermost mannosyl moiety in a par-
tially assembled core glycolipid intermediate (Fig. 3b)
[45–47]. The existence of PIGN-associated deficiency
a
b
Fig. 2 Functional analysis of
PIGN mutants in PIGN-knockout
HEK293 cells. a Restoration of
cell-surface expression of GPI-
anchored protein CD59 on PIGN-
knockout HEK293 cells after
transfection. HA-epitope-tagged,
wild-type T331I, T331S, and
T331V human PIGN cDNAs
were transfected with a medium
promoter-driven pTK vector (top)
or a strong promoter-driven pME
vector (bottom). Three days later,
CD59 levels were assessed by
flow cytometry. bWestern
blotting analysis of wild-type
T331I, T331S, and T331V human
PIGN. PIGN-knockout HEK293
cells that were transfected with
HA-epitope-tagged, wild-type
and mutant PIGN cDNAs in pME
were analyzed 3 days later by
western blotting using anti-HA
antibody. GAPDH
glyceraldehyde 3-phosphate
dehydrogenase, a loading control
a bFig. 3 Structure and synthesis of
GPI. a The core structure of the
GPI anchor is a
phosphatidylinositol moiety, a
glucosamine moiety, three
mannoses, and an ethanolamine
phosphate (EtNP) on the terminal
mannose. The lipid tails of PI are
embedded in lipid rafts in the
plasma membrane, and cell-
surface proteins are bound to the
terminal EtNP. Another EtNP
bound to the first mannose is
found in all mammalian cells. b
PIGN adds the EtNP to the first
mannose during the synthesis of
GPI in the endoplasmic reticulum
[39]
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diseases indicates that this ethanolamine phosphate side chain
has an important biological function, probably related to its
role in the recognition of GPI glycolipids by the transamidase
complex that attaches proteins to the GPI anchors [48]. Flow
cytometry has been used to demonstrate altered expression of
these proteins with mutations of PIGN in humans [38, 49–51].
The variant PIGN:c.398T allele is predicted to result in a
missense mutation, PIGN:p. T133I, in the phosphodiesterase
domain. Evidence that the PIGN:p. T133I substitution partial-
ly impairs biological function was obtained by transiently
transfecting PIGN-knockout HEK293 cells with a human
PIGN cDNA construct designed to encode the p. T133I sub-
stitution. As demonstrated by flow cytometry, the human
PIGN:p. T133I cDNA was ∼60% as effective as wild-type
PIGN cDNA in restoring CD59 surface antigen to the
PIGN-knockout cells. Available sequence information indi-
cates that PIGN orthologs in at least 146 vertebrate species
have a threonine codon at the position orthologous to codon
133 in the human and canine PIGN; however, at least two
vertebrate species, the pig and the cape elephant shrew, have
a serine codon at this position (Supplementary Table 2). This
suggested that the hydroxyl moiety of threonine or serine
might be required for normal biological function. To test this
hypothesis, we transiently transfected PIGN-knockout
HEK293 cells with recombinant human PIGN cDNA de-
signed to encode either PIGN:p. T133S or PIGN:p. T133V.
With both of these constructs, the restoration of CD59 sur-
face antigen was similar to that produced by the wild-type
PIGN cDNA. The apparently normal function of PIGN with
a valine at position 133 indicates that hydroxyl moiety at
this position is not a functional requirement. Nonetheless,
the contrast in flow cytometry patterns obtained with the
various cDNAs substantiates the significance of the 30–
40% decrease in CD59 surface antigen restoration that
was obtained with the cDNA containing the p. T133I
variant.
N-ethyl-N-nitrosourea-derived mice with a homozygous
truncating splice-site mutation in Pign die in utero with
developmental deficiencies including holoprosencephaly
[52]. Similarly, a human fetus died with a diaphragmatic
hernia and many other severe developmental abnormali-
ties, apparently due to a homozygous nullifying splice-site
mutation [53]. Individuals born with other homozygous or
compound heterozygous PIGN mutations share a develop-
mental deficiency syndrome known as multiple congenital
anomalies-hypotonia-seizures syndrome-1 or MCAHS1
(OMIM #614,080). The current literature describes at least
17 MCAHS1 patients from 9 families carrying 13 differ-
ent PIGN mutations [38, 49–51, 54, 55]. These patients
had neonatal hypotonia, severe developmental delays,
congenital anomalies, visual impairment, hyporeflexia,
tremors, and seizures. Some exhibited choreoathetosis
and gait abnormalities, while others had structural brain
abnormalities including delayed myelination, cortical at-
rophy, diffusion restriction in the globus pallidi and
corticospinal tracts, and cerebellar atrophy or parenchymal
loss in the vermis [38, 51, 55]. The severity of clinical
signs in MCAHS1 patients appears to correlate with the
functional severity of the PIGN mutations. The most severe
signs, which included multiple structural and functional
developmental anomalies, occurred in a neonate with a frame-
shift mutation in trans with a multi-exon microdeletion. In
contrast, a child with likely hypomorphic compound
heterozygous missense PIGN mutations showed no
dysmorphic features, moderate developmental delay, and
a later onset of seizures and spastic quadriparesis [55].
The cPxD described in the current report is less severe
than the human and murine PIGN-associated phenotypes.
In contrast to the developmental delays and early mortality
seen in humans [38, 51, 55] and mice [52], respectively,
with loss of PIGN function, the first episodes of dyskinesia
occurred in young-adult dogs. The dogs appeared to be
normal prior to the onset of the dyskinesia and between
episodes. The marked differences in severity may be due
to inherent differences between species. Alternatively, the
differences in severity may occur because the canine muta-
tion encodes a product which retains a relatively greater
amount of residual functional activity. This second possi-
bility is supported by the finding that transfection of
PIGN-knockout HEK293 cells with human T133I PIGN
cDNA in a strong promoter-driven pME vector fully re-
stored CD59 surface expression, whereas a recent report
[38] showed that transfection of PIGN-knockout HEK293
cells with the same strong promoter-driven vector and
PIGN cDNA carrying theMCAHS1-associated S270P resulted
in markedly reduced CD59 surface expression (see Fig. 2b in
reference [38]). Thus, it seems possible that hypomorphic
mutations of human PIGN could also cause PxD or other
disease phenotypes that are less severe than those of
MCAHS1. Similar variability in phenotype is seen in SLC2A1
variants associated with PxD in humans [14, 15, 56].
In summary, we have described a paroxysmal dyskine-
sia in dogs that most closely resembles PNKD but differs
from the known human PxDs; in that, it is autosomal re-
cessively inherited. This disease is very likely caused by a
hypomorphic missense mutation in PIGN, which encodes
an enzyme in the biosynthetic pathway for GPI anchors. If
so, it expands the phenotypes associated with altered GPI
function and suggests candidate genes to investigate in
human PxD that have not had a causal mutation identified.
The spontaneous canine disease could serve as an animal
model to investigate the pathogenesis of PxD and potential
therapies. Nonetheless, we cannot rule out the possibility
that a variant in tight linkage disequilibrium with the
PIGN:c.398C > T transition is the true cause of the disease.
Generation of a mouse model expressing the PIGN:c.398T
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variant that recapitulated the phenotype seen in dogs or the
identification of other PIGN variants in dogs with cPxD
would help confirm that the variant is the causal and permit
further studies on its effect on GPI function and the difference
in phenotype with the null mutations in mice and humans.
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